LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - StockTitan
| LSBPW Stock | 0.04 0 6.29% |
Slightly above 56% of all LakeShore Biopharma's sophisticated investors are looking to take a long position. The analysis of overall sentiment of trading LakeShore Biopharma Co, stock suggests that some investors are interested at this time. LakeShore Biopharma's investing sentiment can be driven by a variety of factors including economic data, LakeShore Biopharma's earnings reports, geopolitical events, and overall market trends.
LakeShore |
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 StockTitan
Read at news.google.com
 |
LakeShore Biopharma Fundamental Analysis
We analyze LakeShore Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LakeShore Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LakeShore Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
LakeShore Biopharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
LakeShore Biopharma Co, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with LakeShore Biopharma stock to make a market-neutral strategy. Peer analysis of LakeShore Biopharma could also be used in its relative valuation, which is a method of valuing LakeShore Biopharma by comparing valuation metrics with similar companies.
Peers
LakeShore Biopharma Related Equities
| VKTX | Viking Therapeutics | 2.84 | ||||
| VNDA | Vanda Pharmaceuticals | 1.52 | ||||
| VRTX | Vertex Pharmaceuticals | 0.20 | ||||
| VRCA | Verrica Pharmaceuticals | 1.14 | ||||
| VSTM | Verastem | 1.80 | ||||
| VRNA | Verona Pharma | 1.87 | ||||
| VRDN | Viridian Therapeutics | 1.96 | ||||
| DWTX | Dogwood Therapeutics, | 2.55 | ||||
| VTGN | VistaGen Therapeutics | 3.09 | ||||
| VRPX | Virpax Pharmaceuticals | 3.13 |
Additional Tools for LakeShore Stock Analysis
When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.